Death, while inevitable, should not result in unnecessary double taxation. For a pharmacist who has spent decades building a professional corporation, the death of the shareholder can create a perfect storm of deemed dispositions, corporate tax on retained earnings, and loss of LCGE eligibility if planning is neglected. Canadian tax law provides several techniques — collectively known as post-mortem tax planning — that can eliminate or mitigate this double taxation. The pipeline strategy is among the most effective when executed carefully with professional guidance.
The double-tax problem
When a pharmacist dies owning shares of a professional corporation, taxation occurs twice unless planned otherwise. At Stage 1, the deemed disposition at death, Income Tax Act subsection 70(5) treats the deceased as having sold all capital property, including corporate shares, at fair-market value immediately before death — creating a capital gain on the shares, which the LCGE may shelter if the corporation is a QSBC. At Stage 2, corporate-level tax, the same corporate earnings that increased the share value remain inside the corporation and are taxed again when later distributed to the estate or heirs as dividends. Without planning, the estate effectively pays tax twice on the same value: once as a capital gain on the shares, and again as dividends on the retained earnings.
The book illustrates the scale. Shares with a $2,000,000 FMV and a $100,000 adjusted cost base, sitting on $1,800,000 of corporate retained earnings, produce a capital gain of about $1.9 million on death; when the retained earnings are later distributed, a further dividend tax of roughly $800,000 can apply. The combined burden of $1.1 to $1.3 million is largely avoidable with planning.
The goals — and the toolkit
Post-mortem planning aims to prevent or reduce double taxation on retained earnings and accrued capital gains, provide liquidity to pay final taxes and redeem shares, enable a smooth transfer of corporate control, maintain QSBC eligibility and CDA integrity, and comply with College ownership and professional-corporation laws. The principal techniques are the pipeline (converting retained earnings to a capital repayment to avoid double tax), the subsection 164(6) loss carry-back (the estate sells shares back to the corporation and applies the resulting capital loss against the gain on the final return), the section 88(1)(d) bump (a step-up in the cost base of underlying assets during a reorganization), amalgamation and wind-up strategies, and insurance-funded redemptions using the CDA. For pharmacists, the pipeline and the 164(6) carry-back are the most common because they coordinate easily with professional-corporation structures.
The pipeline strategy, step by step
The pipeline eliminates double taxation by allowing the estate to extract retained earnings as a capital repayment instead of a dividend. The steps are: at death the estate inherits the shares at fair-market value and the deceased reports the capital gain on the final return; the estate incorporates a new corporation ("Newco"); the estate transfers the deceased's professional corporation ("Opco") shares to Newco under a section 85(1) rollover, receiving a promissory note equal to the FMV of the shares; Newco and Opco amalgamate or Opco is wound up into Newco, so the retained earnings of Opco become available as safe paid-up capital or a tax-free return of capital; and over time Newco repays the estate the promissory note using Opco's retained earnings, with the payments treated as a capital repayment rather than taxable dividends. The CRA generally requires a reasonable delay — often around 12 months — between the amalgamation and repayment to confirm the pipeline's bona fide purpose and avoid recharacterization as a dividend. The result is that only the capital gain at death is taxed; subsequent payments are tax-free, and double taxation is eliminated. Our general post-mortem planning guide covers the technique in more depth.
The subsection 164(6) loss carry-back
Where liquidation is preferable to continuation, subsection 164(6) provides another route. The estate elects to sell the inherited shares back to Opco for FMV, realizing a capital loss; that loss is applied against the capital gain reported on the deceased's final return, refunding part of the tax; and Opco redeems the shares and pays a deemed dividend, taxed at the corporate or estate level. The advantages are that it is simpler and faster than a pipeline, generates an immediate tax refund for the estate, and suits a corporation that will be wound up shortly after death. The disadvantages are that it can cause high dividend tax where retained earnings are large, and that CRA filing deadlines are strict — within one year of death. The book's rule of thumb: use the 164(6) carry-back when the goal is liquidation, and use the pipeline when continuing operations or selling the pharmacy is preferable.
Insurance liquidity and the section 88(1)(d) bump
Corporate-owned life insurance complements post-mortem planning by providing liquidity and CDA credits. On death the Holdco or Opco receives the insurance proceeds tax-free; the proceeds minus the policy's ACB create a CDA credit; the estate receives tax-free capital dividends to pay personal tax or fund a share redemption; and a pipeline or 164(6) plan then eliminates the residual double taxation. This combination ensures the taxes are funded without selling assets or jeopardizing pharmacy operations — a point developed further in our corporate-owned insurance guide. In reorganizations involving holding companies or family trusts, the section 88(1)(d) "bump" can increase the cost base of underlying assets held by a subsidiary when a parent corporation acquires control on death, reducing tax on future sales — for example, bumping the cost base of each subsidiary's goodwill where a Holdco owns multiple pharmacies. The bump is highly technical, and misuse can void the election or trigger a reassessment, so it should be coordinated with an experienced tax lawyer.
The will has to authorize the plan
None of these strategies works unless the executor has authority to carry them out. A pharmacist's will should include express clauses empowering the executor to implement pipeline or loss-carry-back transactions; to amalgamate, wind up, or continue the corporation; to sign and file all tax elections; and to retain accountants and lawyers to execute the plan. A representative sample clause from the book reads: "My Trustee may reorganize, amalgamate, or liquidate any corporation in which I hold an interest and may implement any transactions, elections, or reorganizations that my accountant or tax advisor recommends to minimize taxes payable by my estate." Where dual wills exist for corporate assets, both should grant equivalent post-mortem powers.
Regulatory timing and the family trust
Professional corporations cannot operate indefinitely under a deceased shareholder. Each provincial College imposes deadlines for transfer or sale to maintain pharmacy permits — in Ontario, for example, the College must be notified within 30 days of the shareholder's death, the shares must be sold or transferred to a licensed pharmacist within a prescribed period, and a new pharmacist-director or manager must be designated. The post-mortem reorganization therefore has to be executed swiftly within the compliance window; where no pharmacist heir exists, the share sale or wind-up should be planned in advance through the will or shareholders' agreement. Where a family trust owns pharmacy shares, the trustees should understand the post-mortem options, consider distributing shares to individual beneficiaries before death if timing allows, include incapacity and death-of-trustee clauses so authority for elections is preserved, and align the trust's 21-year-rule planning with the anticipated estate timing.
The pipeline in action
The book's case study follows a pharmacist whose corporation, valued at $3.6 million and consisting entirely of retained earnings, was inherited by an estate facing a potential $1.4 million tax bill. Because the will empowered the executor to implement any post-mortem strategy, the executor incorporated a Newco and transferred the shares under section 85(1), executed a $3.6 million promissory note, amalgamated the two companies after three months, and over two years had Newco repay the note from existing retained earnings. The result: no dividend tax on the distributions, only the initial capital gain taxed on the final return (sheltered by the LCGE), and the CRA accepting the pipeline as a bona fide reorganization. The estimated tax saving was about $650,000, the estate maintained liquidity, and the family retained the pharmacy building through the Holdco. The pipeline remains one of the more efficient and defensible post-mortem strategies when properly documented and executed with professional oversight.
The ethics of post-mortem planning
The book is clear that post-mortem planning is not about aggressive tax avoidance — it is about fairness and continuity. Pharmacists have an ethical duty to ensure that the financial stability of their estate supports, rather than burdens, their family and community. In practice that means communicating intentions to heirs and business partners, documenting the reasoning for the chosen strategies, avoiding aggressive tactics that invite CRA scrutiny or reputational harm, and maintaining transparency with professional advisors and executors. A defensible plan is one that an executor can explain and a reviewer can follow.
A post-mortem planning checklist
The book offers a checklist that doubles as a sequence for the executor: grant executor authority in the will to enable reorganizations and elections; confirm QSBC status at death to maintain LCGE availability; assess the suitability of a pipeline versus a 164(6) carry-back to choose the optimal structure; file elections within the CRA deadlines to avoid a reassessment; maintain corporate minute books to support valuations and elections; use corporate-owned insurance for liquidity so taxes are funded without an asset sale; coordinate with the College on the ownership transfer to ensure compliance; review the integration of the trust and Holdco to prevent fragmentation; retain professional tax and legal counsel to avoid errors and penalties; and communicate the plan to family and advisors to prevent confusion and delay. Because graduated-rate-estate status lasts only 36 months and the 164(6) carry-back must be completed within the estate's first taxation year, much of this work is time-sensitive — the planning that was put in place during the owner's lifetime, such as an estate freeze and a purified corporation, is what makes the post-mortem options work.
Post-mortem planning is the final expression of prudent financial stewardship. By integrating pipeline strategies, loss carry-backs, and insurance liquidity, and by equipping the executor with explicit powers and professional guidance, a pharmacist helps ensure that a life's work continues to support loved ones and the community rather than producing an avoidable tax bill.
This guide draws on Dale Barrett's book "Tax-Wise Estate Planning for Pharmacists" (Barrett Publishing). It is general information about Canadian tax and estate-planning concepts, not legal, tax, or accounting advice; pharmacy ownership rules vary by province and by College, so confirm the current rules and obtain professional advice before acting.